This study aimed to summarize the nursing experience associated with high-flow nasal cannula （HFNC） oxygen therapy in home oxygen therapy for premature infants diagnosed with severe bronchopulmonary dysplasia（sBPD）. A retrospective analysis was conducted using the clinical data of six preterm infants with sBPD who received HFNC-based home oxygen therapy between January 2022 and December 2024. For preterm infants with long-term dependence on home oxygen therapy，a pre-discharge readiness assessment and caregiver empowerment education were implemented. Key interventions included proper administration of home oxygen therapy，development of discontinuation plans based on target blood oxygen saturation （SpO₂） monitoring，appropriate management of adverse events such as choking，asphyxia，and equipment malfunction，as well as structured follow-up protocols. These measures contributed to improved growth and development outcomes and enhanced family quality of life. During the HFNC home oxygen therapy period，among the six infants，only one required hospitalization twice due to milk aspiration and another was readmitted due to rhinovirus infection；the remaining infants completed therapy without complications. During the HFNC home oxygen therapy of the six infants，one infant choked twice and one was readmitted due to rhinovirus infection，while the rest of the infants received HFNC home oxygen therapy smoothly. Among the three weaned infants，one achieved direct oxygen discontinuation after 130 days of home oxygen therapy when the fraction of inspired oxygen（FiO₂） reached 25% and the oxygen flow rate was maintained at 10 L/min. The other two infants received home oxygen therapy for 268 days and 22 days，respectively，followed by a transition to low-flow nasal cannula oxygen therapy prior to successful oxygen weaning. The other three remain under scheduled follow-up.